− Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD − Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M −
PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming event: Chardan Virtual 4th Annual Genetic Medicines Conference October 6, 2020, 1:30 p.m. EDT – Vince Anzalone, CFA, Arrowhead’s vice
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new
- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif. --(BUSINESS WIRE)--Sep.
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 15th Annual BioPharma Virtual Conference September 9, 2020 – Arrowhead management will participate in
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun , M.D., MPH, as an independent director of the company, with a term beginning effective
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 31, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 18, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed